Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916433 · ClinicalTrials.gov registry record · Phase 2
Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
A Phase 2 study, sponsored by Danbury Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02916433 is a Phase 2 study that has completed, run by Danbury Hospital. The registered enrollment target is 5 participants.
The verdict
NCT02916433, a Phase 2 study, has completed, sponsored by Danbury Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether administration of octreotide (12-25 mcg/hour) for 72 hours in combination with the standard of care treatment is effective in reducing bronchorrhea (excessive airway secretions) in mechanically ventilated patients. The use of this drug (octreotide) to manage bronchorrhea has not been approved by the United States Food and Drug Administration (FDA) and is used as an experimental drug in this research study. We are anticipating to enroll approximately 30 subjects in this study at Danbury Hospital, with 15 patients randomly assigned to the "Routine Care" group, which will serve as the control group, and 15 patients randomly assigned to the octreotide group. Control group will only receive the standard of care and will not receive this drug. Total subject participation in this study will be for 4 days (96 hours) or until their breathing tube is removed (extubation), whichever occurs first.
Interventions
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916433
The ClinicalTrials.gov registry entry for NCT02916433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Danbury Hospital, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octreotide is the first listed.
NCT02916433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02916433 about?
NCT02916433 is a clinical study titled "Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients". The purpose of this study is to determine whether administration of octreotide (12-25 mcg/hour) for 72 hours in combination with the standard of care treatment is effective in reducing bronchorrhea (excessive airway secretions) in mechanically ventilated patients. The use of this drug (octreotide) t...
What is the current status of trial NCT02916433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2016-09. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02916433?
The interventions under investigation include: Octreotide (DRUG).
Who is sponsoring clinical trial NCT02916433?
This trial is sponsored by Danbury Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.